Phase I study of biweekly paclitaxel and carboplatin administration in patients with advanced non-small cell lung cancer |
| |
Authors: | Ichiki Masao Rikimaru Toru Gohara Rumi Oshita Yuichi Kamimura Tomoko Hoashi Shigehisa Koga Takeharu Aizawa Hisamichi |
| |
Institution: | First Dept. of Medicine, Kurume University, School of Medicine. |
| |
Abstract: | A phase I study of a biweekly outpatient regimen composed of carboplatin (CBDCA) and paclitaxel (TXL) was conducted for advanced non-small cell lung cancer. TXL was given in combination with a fixed dose of CBDCA (AUC 3) every 2 weeks. The starting dose of TXL was 100 mg/m2, and the dose was escalated in increments of 20 mg/m2. Three to six patients were allocated to each level. Toxicities were evaluated in the first 4 courses to determine the maximum tolerated dose (MTD). TXL 160 mg/m2 dosages proved to be MTD, and the dose limiting toxicity (DLT) was hematotoxicity (neutropenia). The patients, however, recovered from neutropenia using G-CSF immediately, when G-CSF was used. Gastrointestinal toxicity was well-tolerated. A response was found in 9 out of 20 patients who received 4 courses or more (45%). These results suggest that the recommended dose would be CBDCA (AUC 3) + TXL 140 mg/m2. The biweekly regimen has a high level clinical activity and excellent tolerability, and is suitable for outpatients. We started a phase II study because of these results. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|